19 October-30 November 2020
The 51st Union World Conference On Lung Health
REGISTER NOW

Sessions

All Sessions
keyboard_arrow_down
keyboard_arrow_down Show filters keyboard_arrow_up Hide filters
  • All Tracks
  • Community Connect
  • Channel 1
  • Channel 2
  • Channel 3
  • Channel 4
  • Channel 5
  • Channel 6
  • Channel 7
  • E-posters
  • Workshops
Channel 1
Opening Ceremony
event_note
Loading...
query_builder 14:00 - 15:00 | Event time (GMT+1)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Opening Ceremony
mic English
Opening Ceremony
*Please scroll down for more information*
Opening Ceremony: Marking The Union's Centennial Year
20 October 2020              2PM-3PM CEST
 
On 20 October 1920, representatives from 31 countries, recognising that a global health crisis – tuberculosis – could not be defeated without international collaboration and knowledge sharing, came together and founded The Union. One hundred years later, as the world struggles to confront a new infectious respiratory disease – COVID-19 – our founders’ vision remains as relevant as ever.

As The Union turns a century old, we also embark upon the first ever virtual Union World Conference. The opening ceremony will reflect on the journey so far and the distance left to travel.
 
We will hear from:
 - Her Imperial Highness Crown Princess Akishino of Japan
- President Bill Clinton
- World Health Organization Director-General Dr Tedros Adhanom Ghebreyesus
- Yvonne Chaka Chaka, singer, entrepreneur, Global Health Advocate and humanitarian
- Divya Sojan, TB survivor and nurse
- Shannon Hader, Deputy Executive Director United Nations Programme on HIV/AIDS (UNAIDS)
- Katherine Maher, Chief Executive of the Wikimedia Foundation (Interviewed by Noam Cohen, WIRED)
- Claire Forlani, UK Film and TV Actress, and The Union’s TB Ambassador
- Dr Tamaryn Green, TB Survivor, Medical Doctor, Miss South Africa 2018
 
President of The Union, Professor Guy Marks, The Union’s Executive Director, José Luis Castro, and Dr Keren Middelkoop, Chair Coordinating Committee of Scientific Activities will also speak.

Please join our opening ceremony and we wish you an inspiring virtual Union World Conference.

Loading...
Channel 4
MTE-02-Meet the expert session: Adult and Child Lung Health
event_note
Loading...
query_builder 9:45 - 10:45 | Event time (GMT+1)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Meet the expert session
mic English
MTE-02-Meet the expert session: Adult and Child Lung Health
*Please scroll down for more information*
TB vaccine for children

Please note that the number of participants is limited for this session.

Loading...
Channel 3
MTE-01-Meet the expert session: civil society
event_note
Loading...
query_builder 9:45 - 10:45 | Event time (GMT+1)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Meet the expert session
mic English
MTE-01-Meet the expert session: civil society
*Please scroll down for more information*

Health advocacy for access to care

Alternative respond to Covid-19 by the Civil Society Organisations in South Africa

Please note that the number of participants is limited to 50 for this session.

Loading...
E-posters
EP07-Improving TB care in children
event_note
Loading...
query_builder 10:00 - 11:00 | Event time (GMT+1)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel E-poster session
mic English
EP07-Improving TB care in children
*Please scroll down for more information*
All E-posters are accessible via the "E-posters" section of the conference platform until 30 November.

EP07-159-21-Detecting and preventing paediatric TB through systematic household contact investigations in nine sub-Saharan countriesWe describe yields in tuberculosis (TB) detection and TB preventive therapy cascades - from screening to treatment completion - obtained during an intervention supporting systematic household contact investigation of paediatric TB index cases across nine sub-Saharan countries.
Jean-Francois Lemaire

EP07-160-21-Paediatric TB detection and treatment cascade in nine sub-Saharan countries following the CaP-TB interventionWe prospectively documented retention in the paediatric tuberculosis (TB) care cascade - from screening to treatment outcomes - during a comprehensive intervention, including paediatric specific systematic symptoms screening in health facilities, increased access to Xpert MTB/RIF testing, intensified household contact investigation and treatment of drug-sensitive TB with child-friendly formulations across nine sub-Saharan countries.
Shirin Kakayeva

EP07-161-21-Increasing paediatric TB detection and treatment in private health sector in IndiaWe share findings from the intervention on integrating comprehensive paediatric tuberculosis (TB) care cascade among private healthcare facilities in India. This includes evidence from intensified case finding activities in private facilities, enhancing their access to government’s free Xpert MTB/RIF diagnostics and WHO approved child-friendly fixed dose combination (FDC) dispersible drugs.
Karun Sandeep Veesa

EP07-162-21-Training physicians in India to interpret paediatric chest radiographs according to World Health Organization research methodologyChest radiography is the standard for diagnosing paediatric lower respiratory infections in low- and middle-income countries. Research in India required training local physicians to interpret chest radiographs following an updated World Health Organization interpretation method. We described the methodology for training Indian physicians and evaluated the training’s effectiveness.
Eric D McCollum

EP07-163-21-Care cascade of contact screening and preventive therapy among children under five in high-burden districts of NepalContact screening and provision of preventive therapy for under 5s as one intervention to prevent childhood TB in 38 high-burden districts of Nepal from 2017. Care cascade constructed in this paper focuses on contract tracing done during the period of March 2018-Dec 2019.
Suvesh Kumar Shrestha

EP07-164-21-Paediatric latent TB infection cascade of care from the TB and Leprosy Free Majuro community mass screening projectTB and Leprosy Free Majuro was a tuberculosis/latent tuberculosis infection (TB/LTBI) mass screening campaign implemented by the Republic of the Marshall Islands' Ministry of Health, on Majuro Atoll, from June to November 2018. It offered screening and treatment for LTBI in children 0-14 years old with varying success depending on age cohort.
Rachel Dwilow

EP07-165-21-Improvement of screening for childhood TB in Senegal coupled with screening for malnutrition: pilot study in the health districts of Thiès and Tivaouane, SénégalWe carried out operational research on the integration of the two tuberculosis (TB) and malnutrition control programmes to improve the screening of these diseases in children aged 0 to 14. This research developed by OMS/TDR shows that it can help the programme to improve the screening of childhood TB in Senegal.
Nafissatou Oumar Toure

EP07-166-21-Barriers to uptake of isoniazid preventive therapy among eligible child household contacts of TB patients in Southern NigeriaThis research explores the barriers to the uptake of isoniazid preventive therapy among eligible child contacts (under 6 years of age) of TB patients in six states of Southern Nigeria. Study findings highlight both patients and health systems factors.
Chukwuka Alphonsus

EP07-167-21-The state of paediatric, rifampicin-resistant TB in Khayelitsha, South AfricaOutcomes for paediatrics who receive rifampicin-resistant TB (RR-TB) treatment are excellent. Despite universal access to Xpert in South Africa, the frequency of paediatric cases detected has not increased, suggesting that diagnosis of RR-TB in paediatrics remains a challenge. Efforts to improve case detection, contact assessment and appropriate treatment initiation are urgently needed.
Johnny Daniels

Loading...
E-posters
EP02-Challenges for randomised controlled trials on TB treatment
event_note
Loading...
query_builder 10:00 - 11:00 | Event time (GMT+1)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel E-poster session
mic English
EP02-Challenges for randomised controlled trials on TB treatment
*Please scroll down for more information*
All E-posters are accessible via the "E-posters" section of the conference platform until 30 November.

EP02-110-21-International multicentre controlled trial to evaluate 1200mg and 1800mg rifampicin daily in the reduction of treatment duration for pulmonary TB from six to four monthsThe current treatment for drug-sensitive pulmonary tuberculosis (TB) involves taking drugs daily for six months. RIFASHORT is an international multicentre controlled clinical trial which evaluates higher doses of rifampicin with the objective of reducing the treatment duration for drug-sensitive pulmonary TB from six months to four months.
Tulika Munshi

EP02-111-21-Documenting challenges faced and lessons learned from implementation of STREAM – the world’s largest recruited multidrug-resistant TB clinical trialMulticountry clinical trial implementation is complex – from different regulatory requirements and approval processes to variable research infrastructure and capacity across settings. Here, we document challenges faced and lessons learned from STREAM – the first large-scale, multicountry clinical trial for multidrug-resistant tuberculosis.
Meera Gurumurthy

EP02-112-21-A method for baseline adjudication of TB diagnosis in children in a therapeutic clinical trial: experience from SHINEDiagnosing non-severe pulmonary tuberculosis (TB) in children is challenging.  Results in children adjudicated as having TB (in the SHINE trial comparing four vs six months of standard therapy) will be essential. The approach to adjudicate TB or not TB can help overcome challenges in paediatric TB studies in the absence of gold standard diagnostic tests.
Genevieve H Wills

EP02-113-21-Sustainability of the ACT4 randomised trial to improve initiation of TB preventive treatmentThe ACT4 randomised trial found that a health systems' intervention in strengthening management of latent tuberculosis (TB) infection was effective at increasing TB preventive therapy initiation rates in households contacts. In this follow up study, the sustainability of the ACT4 intervention was evaluated over the nine months following the end of the trial.
Olivia Oxlade

EP02-114-21-Utility of colour vision testing in screening for ethambutol-associated ocular toxicity in children treated for TB in the SHINE trialEthambutol-associated ocular toxicity (EAOT) is reported in 0.05-0.7% of children treated for tuberculosis (TB). Using a child-friendly colour vision test as a screening tool, there was no evidence of clinically significant EAOT in children taking ethambutol.  Colour vision testing in children is feasible but may not be necessary for standard drug-sensitive TB treatment.
Eric Wobudeya

EP02-115-21-Adolescents in a TB clinical treatment trial: characteristics of an under represented populationAdolescents represent approximately 10% of the global tuberculosis (TB) burden yet they are historically under represented in clinical trials, potentially limiting their access to new treatments. We examined enrolment patterns for adolescents in a TB Trials Consortium and AIDS Clinical Trials Group Phase III and rifapentine-containing treatment shortening trial for pulmonary TB (NCT02410772).
Kimberley Hedges

EP02-116-21-Investigator reported barriers and facilitators to adolescent recruitment, enrolment and retention in TB Trials Consortium Study 31/ACTG A5349In a randomised, phase III treatment shortening trial for drug-susceptible pulmonary tuberculosis, we evaluated barriers and facilitators of adolescent participation in clinical trials. Using the capability, opportunity, motivation and behaviour model, we constructed interview guides, conducted interviews with principal investigators across two research consortia and analysed interview transcripts.
Joan Mangan

EP02-117-21-Exploring antagonism in anti-TB drugs using a hollow-fiber modelIsoniazid is part of the frontline anti-tuberculosis (TB) regimen. We have shown that its inclusion in a rifampicin/isoniazid dual therapy model increases the incidence of drug-tolerant, lipid-rich cells that stain as if respiring but with a compromised cell wall. This data is indicative of clearance antagonism occurring in TB chemotherapy.
Robert Hammond

Loading...
E-posters
EP09-Improved acceptability of TB regimens needed
event_note
Loading...
query_builder 10:00 - 11:00 | Event time (GMT+1)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel E-poster session
mic English
EP09-Improved acceptability of TB regimens needed
*Please scroll down for more information*
All E-posters are accessible via the "E-posters" section of the conference platform until 30 November.

EP09-176-21-Risk factors for cycloserine neurotoxicity in patients treated for multidrug-resistant TBCycloserine has been re-classified as a category B drug by the World Health Organization. The neurotoxicity associated with cylcoserine has limited its use in treatment programmes. We systemically collected neurotoxicity data in patients in Cape Town treated with cycloserine, dosed as terizidone, for multidrug-resistant TB. We then evaluated factors, including cycloserine AUC, with neurotoxicity.
Richard Court

EP09-177-21-Hearing loss on second line injectable therapy for rifampin-resistant TB in a retrospective cohort in Worcester, South AfricaSecond line injectables (SLIs) remain a part of the drug-resistant TB regimen in many settings globally, even with SLI-induced ototoxicity rates remaining high. In this South African rifampin-resistant TB cohort, regimen adjustments due to hearing loss were common, further emphasising the need for access to SLI-sparing regimens.
Tara C Bouton

EP09-178-21-Treatment outcome of shorter regimen for multidrug-resistant TB in Pakistan 2018The National Tuberculosis (TB) Programme in Pakistan recommended a shorter regimen of nine-11 months in January 2018 under programmatic settings in all PMDT sites of the country. We compared treatment outcome of patients who were put on the shorter regimen, with those who were eligible for the shorter regimen but who were put on the longer one.
Abdul Ghafoor

EP09-179-21-From pilot to nationwide scale-up of shorter treatment regimen for drug-resistant TB treatment: lessons from NigeriaFollowing the adoption and rapid scale-up of GeneXpert as a primary tuberculosis (TB) diagnostic tool, limited bed spaces resulted in the challenge of a huge number of diagnosed drug-resistant TB (DR-TB) patients on treatment waiting lists. The CTB project facilitated nationwide scale-up of STR and NDs, including establishing aDSM for newly diagnosed DR-TB patients.
Sani Useni

EP09-180-21-Preferences for shorter regimens and child-friendly formulations for TB preventive treatment among families affected by TB in Lima, PeruFocus group discussions with families affected by tuberculosis (TB) in Lima, Peru, explored preferences for TB preventive treatment regimens, for both adult and child contacts, and sought to understand the drivers behind these preferences.
Courtney Yuen

EP09-182-21-Safety and efficacy of allogeneic γδ T cells for multidrug-resistant TB: an interim analysis of a prospective single centre, open labeled, non-randomised, controlled matched trialAnti-tuberculosis (TB) drugs for multidrug-resistant (MDR-TB) and rifampicin-resistant TB (RR-TB) currently encounter many obstacles and host-directed therapy approaches are now a focus for use as adjunct treatment options for shortening duration, limiting immunopathology, and improving outcomes. The safety and efficacy of γδT cells have been studied in our pilot trial, which is the first one worldwide.
Liang Fu

EP09-183-21-Interim outcomes of bedaquiline-containing regimen for the treatment of MDR/XDR-TB — a prospective cohort study from Hunan, ChinaChina introduced bedaquiline relatively late and little data exists on its use outside clinical trials. We conducted  a prospective cohort study to evaluate the effectiveness and safety of bedaquiline-containing regimen for 24 weeks intensive treatment of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis (MDR/XDR-TB) in Hunan province, China.
li shi

EP09-184-21-Treatment interruption patterns among patients on bedaquiline- containing regimen under programmatic conditionsThis was an observational study, including 275 consecutively enrolled tuberculosis (TB) patients, who received a bedaquiline-containing regimen under the national TB programme in India. The study analysed the reasons for interruptions of treatment and loss to follow-up and their effect on interim treatment outcomes during the first six months of treatment.
Rupak Singla

EP09-185-21-Incidence rate of linezolid adverse events among Myanmar adult MDR/RR-TB patients on individualised longer drug-resistant TB regimensLinezolid, a Group A drug, has evidences for significant treatment success but it also has common, serious adverse events such as myelosuppression and peripheral neuropathy. The study determined the incidence rate of linezolid adverse events and characterised the safety of linezolid among Myanmar adult multidrug-resistant and rifampicin-resistant tuberculosis (TB) patients who were on individualised, longer drug-resistant TB regimens.
Thandar Hmun

EP09-186-21-Real-time payment of Nikshay Poshan Yojana under direct benefit transfer scheme improved overall notification, treatment adherence and outcome of TB and DR-TB patients in Odisha, IndiaReal-time payment of Nikshay Poshan Yojana under a direct benefit transfer scheme improved the overall notification, treatment adherence and outcome of tuberculosis (TB) and drug-resistant TB patients in Odisha, India. The National TB Programme performance rank in the Odisha state went up from 27th to 15th during 2019.
Gayadhar Mallick

Loading...
E-posters
EP06-TB: data matters
event_note
Loading...
query_builder 10:00 - 11:00 | Event time (GMT+1)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel E-poster session
mic English
EP06-TB: data matters
*Please scroll down for more information*
All E-posters are accessible via the "E-posters" section of the conference platform until 30 November. .

EP06-152-21-Assessment of TB underreporting by level of reporting system in Lagos, NigeriaAssessment of tuberculosis (TB) underreporting by level of reporting system, Nigeria. It was a quantitative, descriptive study using secondary data from an inventory study on TB reporting knowledge, attitude and behaviour conducted in 2017 in Lagos State to assess TB underreporting by type and level of health facilities, including associated factors.  
Mustapha Gidado

EP06-153-21-Improving TB treatment outcomes through effective linkage of transfer out patientsThe transfer out tool proved to be an effective strategy in referral and linkage for all tuberculosis (TB) patients who prefer continuum of care at facilities of their convenience. TB control programmes should consider adopting this tool and roll it out to all TB sites to improve quality of care. 
Stella Omulo

EP06-154-21-Nationwide surveillance of emerging isoniazid resistance after implementation of isoniazid preventive therapy for TB contactsAlthough population isoniazid resistance does not increase due to isoniazid preventive therapy, consider to provide isoniazid resistance as a priority of developing rapid drug susceptibility test for individuals who have developed TB after isoniazid preventive therapy can further advance propagation of prevention programme with trust.
Pei-Chun Chan

EP06-155-21-Review of the epidemiological mathematical modelling literature to inform TB vaccination development and strategiesMathematical models provide valuable information to aid the development of tuberculosis (TB) vaccines and vaccination strategies. Evaluating the impact of different vaccine characteristics in varied epidemiological settings such as exploring age, spatial hotspot and risk group targeting, as well as accounting for HIV, multidrug-resistance and population endemicity, can inform country-level implementation of novel TB vaccines.
Rebecca A. Clark

EP06-156-21-Strengthening hospital DOTS linkage using ad hoc staff to find missing TB cases: The Aminu Kano Teaching Hospital ExperienceAminu Kano Teaching Hospital (AKTH) is the largest tertiary facility in Kano state with an average daily hospital attendance of 862 patients. We sought to improve facility based active case finding by engaging trained ad hoc staff and deploying them across service delivery points over a period of time.
Mamman Bajehson

EP06-157-21-Incorporating patient reporting patterns to evaluate geographically targeted TB interventions in Dhaka, BangladeshTuberculosis (TB) is geographically heterogeneous and geographic targeting can improve the impact and efficiency of TB interventions. However, standard TB notification data may not sufficiently capture this heterogeneity. Better understanding of patient reporting behaviour may improve our ability to use notifications to appropriately target interventions.
Isabella Gomes

EP06-158-21-Lessons from a data quality assessment of TB notifications in Zambia: the case of under notification in a national TB programmeNational tuberculosis (TB) programmes should conduct periodic data quality assessments (DQAs) to validate notifications data. Findings will be very useful in designing future programming and implementation. The findings underscore the urgent need to strengthen the linkage to care. National TB programmes could potentially increase the TB treatment coverage by restoring data management systems.
Patrick Lungu

Loading...
E-posters
EP01-Resisting the resistance
event_note
Loading...
query_builder 10:00 - 11:00 | Event time (GMT+1)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel E-poster session
mic English
EP01-Resisting the resistance
*Please scroll down for more information*
All E-posters are accessible via the "E-posters" section of the conference platform until 30 November.

EP01-100-21-Pharmacokinetics of anti-TB drugs in multidrug-resistant TB patients in IndiaA pharmacokinetic (PK) study of drugs used to treat multidrug-resistant (MDR) tuberculosis (TB) was undertaken in 350 adult MDR-TB patients treated according to the prevailing guidelines in India. Factors influencing drug PK and end of intensive phase status were also determined. Results of this study will be discussed.
Agibothu Kupparam Hemanth Kumar

EP01-101-21-Multidrug-resistant TB and its determinants of health service, community and social context in the state of São Paulo, BrazilThis study presents the social determinants of health in relation to the occurrence of multidrug-resistant tuberculosis, key information for disease control in regions with great social inequity. We emphasise the importance of socioeconomic, demographic and health system structure conditions for the spread of the disease.
Ricardo Arcêncio

EP01-102-21-Decentralised care for rifampicin-resistant TB in Western Cape, South Africa: a laboratory cohort studySouth Africa implemented a policy to decentralise rifampicin-resistant tuberculosis (RR-TB) care in 2011. We used laboratory data from the Western Cape province to assess patterns of RR-TB care and identify changes in hospitalisation rates, length of hospital stay and travel burden from 2012-2014. We compared Cape Town with more rural districts.
Helen Jenkins

EP01-103-21-Effectiveness, safety and feasibility of nine-month treatment regimen for rifampin-resistant TB in the PhilippinesThe short nine-month multidrug-resistant tuberculosis regimen had a high treatment success rate (74 percent) with a favourable safety profile in a prospective single-arm study conducted in the Philippines during 07/2015-12/2016. Nine-month treatment regimen operational research had a major impact on building national capacity and infrastructure for programmatic adoption of the new regimen in country.
Vivian Lofranco

EP01-104-21-Characterising multidrug-resistant tuberculosis transmission in rural KwaZulu-Natal: a prospective cohort studyThis study combined whole genome sequencing of 129 Mycobacterium tuberculosis (Mtb) isolates with demographic data from patients with multidrug-resistant TB in KwaZulu-Natal, South Africa. Transmission clusters based on genomic differences were identified. Relationships between demographic characteristics, Mtb lineage, rpoB mutation and transmission clustering were examined, aiming to elucidate drivers of Mtb transmission.
Cassandra Fairhead

EP01-105-21-Effectiveness and safety of use of bedaquiline and delamanid in combination for drug-resistant extrapulmonary TB in Mumbai, IndiaMédecins Sans Frontières has been providing treatment, including bedaquiline and/or delamanid, to patients with drug-resistant tuberculosis (TB) in Mumbai since 2015. Cases are referred with complex resistance profiles and extensive treatment history. This study aims to describe the effectiveness and safety of use of bedaquiline and delamanid for drug-resistant extrapulmonary TB.
Himani Mongia

EP01-106-21-Eliciting patient preferences for different attributes of a community-based model for management of multidrug-resistant TB in Uganda: a discrete choice experimentThe advent of all-oral regimens for the management of multidrug- resistant tuberculosis makes the implementation of home-based treatment a possibility for this group of patients. However, to be successful, options for home-based care should take into consideration patient preferences for different aspects of care.    
Stella Zawedde-Muyanja

EP01-107-21-Treatment of multidrug-resistant TB with modified shorter all-oral treatment regimen: Belarus operational research studyIn October 2018, Belarus started to use mSTR for multidrug-resistant tuberculosis under operational research conditions. By 1st May 2020, 415 patients were included in the study and, of them, 114 had final treatment outcomes with encouraging results (89% of treatment success).
Alena Skrahina

EP01-108-21-Patient’s perspective on drug-resistant TB medication: does it matter? Putting research into action to develop information, education and communication materialA qualitative study of drug-resistant tuberculosis (DR-TB) treatment from the perspective and experience of patient, family, healthcare worker and psychologist in six health facilities within three districts of Indonesia as a basis for developing DR-TB information, education and communication material based on the Health Belief Model and Transtheoretical Model.
Ferdiana Yunita

EP01-109-21-The role of clinical healthcare champions in driving drug-resistant TB policy implementation in South AfricaIn South Africa, champions have emerged as a driving force behind the implementation of decentralised management of drug-resistant tuberculosis (DR-TB). This study explored the typology of champions in the decentralisation of DR-TB management, strategies that champions used to implement policy and the contextual factors that enabled or hindered their agency.
Sacha Le Roux

Loading...
E-posters
EP10-Overcoming barriers in the contact cascade of care
event_note
Loading...
query_builder 10:00 - 11:00 | Event time (GMT+1)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel E-poster session
mic English
EP10-Overcoming barriers in the contact cascade of care
*Please scroll down for more information*
All E-posters are accessible via the "E-posters" section of the conference platform until 30 November.

EP10-187-21-A missed opportunity: active contact investigation of diagnosed TB patients in NigeriaPeople who have been in close contact with bacteriologically confirmed pulmonary tuberculosis (TB) patients constitute a high-risk group for developing TB disease. Active household contact investigation of index TB patients demonstrates a great opportunity to increase a diverse pool of human resources, capacity to diagnosis and to notify additional TB cases.
Sani Useni

EP10-188-21-Risk of developing active multidrug-resistant TB among contacts in Taiwan, 2016-2018Identifying at-risk contacts, who have been exposed to a multidrug-resistant tuberculosis (MDR-TB) index patient, to see if they develop active disease would help advancing prevention of MDR-TB in Taiwan. In addition, active follow-up and prioritising those household or IGRA-positive contacts for latent TB treatment may further decline the incidence of MDR-TB. 
Pin Hui Lee

EP10-189-21-Utility of interferon gamma/tumor necrosis factor alpha FluoroSpot assay in differentiation between active TB and latent TB infection: a pilot studyWe aimed to provide a highly sensitive and practical auxiliary method for tuberculosis (TB) differential diagnosis. In this abstract, we demonstrated the diagnostic accuracy of the interferon gamma/tumor necrosis factor alpha (IFN-γ/TNF-α ) FluoroSpot assay for differentiating active TB from latent TB infection. 
Ziyue Zhou

EP10-190-21-Results of management latent TB infection in Quang Nam province, Viet Nam, 2017-2018Results of the management of latent tuberculosis (TB) infection during the period of 2017-2018 in Quang Nam province, Viet Nam. Interventions have shown to be effective in increasing the ability to identify, screen TB and treat latent TB infection among household contacts of TB patients.
LV Vinh

EP10-192-21-Effectiveness of contact tracing intervention for improving TB case detection in NigeriaSystematic investigation of contacts of index TB cases for active disease has remained a priority active case finding strategy. Stakeholders for tuberculosis (TB) control need to apply the right strategy, job aid, tools and training for health workers to help standardise TB information and empower communities with the right TB knowledge
Chidubem Ogbudebe

EP10-193-21-Dilemma in contact investigation: to expand or notContact investigation as a part of Dutch tuberculosis (TB) policy aims for early case detection, treatment and prevention of TB transmission. Risk assessment forms a basic approach to the organisation of contact investigation.
Sophie Toumanian

EP10-194-21-Piloting a shortened regimen for the treatment of latent TB infection in two provinces of Viet NamIn 2019, Friends for International TB Relief, together with the Viet Nam National TB Programme, implemented community-based tuberculosis (TB) case finding campaigns with integrated latent TB infection testing and treatment using a shortened regimen in two provinces of Viet Nam. We herein describe the results of these activities.
Thuy Thu Thi Dong

EP10-195-21-Prevalence of latent TB infection and predictive factors among working-age population in urban and rural area of Northern Guangdong, China: a cross-sectional studyChina has one of the highest burdens of latent tuberculosis (TB) infection (LTBI). Studies, which mainly focused on high-risk population, observed LTBI prevalence ranging from 9% up to 70%. The goal of this study was to describe LTBI burden in the general population, especially in those of working age, and determine its associated factors.
Fangjing ZHOU

EP10-196-21-Impact of civil society advocacy on the introduction of TB LAM testing in PEPFAR-eligible countriesUptake of tuberculosis (TB) LAM testing in high TB and HIV burden countries has been limited despite a demonstrated mortality benefit among people with advanced HIV. We reviewed FY2018 and FY2019 PEPFAR country operational plans to evaluate the impact of advocacy on TB LAM uptake in PEPFAR-eligible countries.
David Branigan

Loading...
E-posters
EP03-Digital technology in the fight against TB
event_note
Loading...
query_builder 10:00 - 11:00 | Event time (GMT+1)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel E-poster session
mic English
EP03-Digital technology in the fight against TB
*Please scroll down for more information*
All E-posters are accessible via the "E-posters" section of the conference platform until 30 November.

EP03-118-21-Implementation of artificial intelligence for presumptive TB screening in Nagpur, IndiaIntroduction of newer technologies such as artificial intelligence in detection of diseases including tuberculosis (TB) are being piloted for efficacy and effectiveness. One such tool - qXR - was implemented for chest x-ray screening followed by microbiological testing for confirmation of TB. Lessons learned from the pilot can be used for scale-up.
Shibu Vijayan

EP03-119-21-Decentralised drug-resistant TB treatment challenges in South Africa and options for implementation of a smartphone application based on latest guidelinesSouth Africa has the third highest number of notified cases of drug- resistant tuberculosis. We discuss use of behaviour change theory to understand key barriers to awareness of, and access to, new care and treatment guidelines, as well as the development of a novel point-of-care decision supporting smart phone application.
Susanne Luedtke

EP03-120-21-Disease patterns on computer-assisted chest radiography in a community-based prevalence survey for TBCommunity-wide active case finding (ACF) for tuberculosis (TB) is a proposed intervention to reduce the burden of the disease. Computer-assisted radiography is an essential tool in the ACF intervention and can potentially be used to screen for undiagnosed, non-communicable diseases. We described the observations from a prevalence survey in communities in Blantyre.
Hussein Twabi

EP03-121-21-Integrated digital adherence technologies for TB: determinants of technology-derived adherenceThe Integrated Digital Adherence Technology Initiative (IDAT) enroled 12,100 patients in various technologies - 99DOTS (directly observed treatment, short course), MERM (medication event reminder monitor system, and video observed therapy (VOT) - across eight districts and three states in India. Heterogeneity in the outcome measure of technology-derived adherence is observed with various systems, technology and temporal and patient-level factors, affecting DAT uptake and engagement. 
Sirisha Papineni

EP03-122-21-Implementing a referral system for drug-resistant TB patients to maximise treatment linkages to the public sector and minimise the treatment initiation time in Mumbai, IndiaAchieving early elimination requires a strong referral mechanism where patient and private hospitals engage throughout the treatment. PATH is collaborating with the Mumbai Corporation to link privately diagnosed drug-resistant tuberculosis patients to the public sector. Effective referral mechanism and implementation strategy has resulted in successful patient linkages to the public sector.
Dnyaneshwar Waman

EP03-123-21-Methods for estimating spatial and time-varying transmission patterns of TB in Espirito Santo, Brazil, between 2005-2013Tuberculosis (TB) case notification data is often collected for surveillance. We describe a method to estimate reproductive numbers with spatial variability using this data. We correlate estimated reproductive numbers in four municipalities in Espirito Santo, Brazil, with data from a concurrent household contact study and RFLP to understand transmission dynamics.

Benjamin Rader

EP03-124-21-eHealth in the future of TB medicines management: a case of a TB medicines web-based ordering and reporting system in UgandaIn developing countries, healthcare systems face major challenges with tuberculosis (TB) medicines management and reporting. Electronic TB medicines ordering and reporting systems facilitate information gathering for healthcare decision support by enhancing the speed and accuracy of data transmission and better stock monitoring, thus ensuring uninterrupted medicine availability.
Hawa Nakato

EP03-125-21-How can we find TB patients not linked to care? Lessons learned from a systematic tracing process implemented in the Western Cape Province, South AfricaTuberculosis (TB) case finding and treatment initiation is a major challenge in the Western Cape, South Africa. Linkage to care has individual benefits and reduces risk of onward transmission. Patient case finding requires use of different strategies, creativity and flexibility. 
Nosivuyile Vanqa

EP03-126-21-An assessment of the effectiveness of mobile community-based TB screening in Blantyre, Thyolo and Mwanza, in MalawiMobile van intervention has proved to be a viable strategy in finding missing active tuberculosis (TB) cases. All cases have been referred to the nearest hospitals for treatment and proper management. Sustainability of this intervention within the National TB Control Programme will see Malawi achieving its goal of ending TB infection in the country.
Allan Chimpeni

EP03-127-21-Decentralising access to digital information management to treatment supporters level for efficient real-time patient managementTreatment supporters (TS) counsel and follow up with TB patients until treatment completion. With Nikshay, India’s TB patient management system, treatment supporters can log in and update a TB patient’s health record. On treatment completion, the TS' honorarium can be processed digitally without delay.
Manu Easow Mathew

Loading...
Processing. Please wait.
Loading...